Why Qiagen N.V.’s (QGEN) Stock Is Up 9.50%
As of Thursday, July 09, Qiagen N.V.’s QGEN share price has surged by 9.50%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Commentary & Analysis
Which Is a Better Investment, AbCellera Biologics Inc. or Qiagen N.V. Stock?
Learn more about whether AbCellera Biologics Inc. or Qiagen N.V. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Michael Rose
Why Qiagen N.V.’s (QGEN) Stock Is Up 5.13%
As of Wednesday, June 24, Qiagen N.V.’s QGEN share price has surged by 5.13%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Qiagen N.V.’s (QGEN) Stock Is Down 7.32%
As of Tuesday, April 28, Qiagen N.V.’s QGEN share price has dipped by 7.32%, which has investors questioning if this is right time to buy.Michael Rose
Why Qiagen N.V.’s (QGEN) Stock Is Down 5.58%
As of Thursday, April 23, Qiagen N.V.’s QGEN share price has dipped by 5.58%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | QGEN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $8,561.5 | $1,790.4 | 75% |
|
| Shares Out (Mil) | 208.9 | 94.8 | 77% |
|
| Institutional Ownership | 99.3% | 90.0% | 87% |
|
| Float (Mil) | 205.3 | 69.9 | 75% |
|
| Beta | 0.66 | 1.20 | 38% |
|
| Avg Daily Volume (000s) | 2,026 | 814 | 82% |
|
| Price Change (52-week) |
(22.2%) | 80.2% | 29% |
|
| Growth | QGEN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 2.2% | 7.8% | 24% |
|
| Net Income (5yr) | 3.4% | (13.7%) | 44% |
|
| EPS (5yr) | 3.6% | 0.7% | 36 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 50.3% | (15.0%) | 93% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 10 | 12 | 14 | |
| Current EPS | $0.600 | $2.440 | $2.623 | |
| Month Ago EPS | $0.603 | $2.430 | $2.638 | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | $0.610 | $2.467 | $2.682 | |
| Year/Year Chg | 82.4% | 19.5% | 41.2% | |
| Financials | QGEN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2,099 | $785 | 61% |
|
| Net Income (TTM) (Mil) | $402 | ($14) | 76% |
|
| EPS (TTM) | $1.950 | ($0.200) | 71% |
|
| Operating Cash Flow (TTM) (Mil) | $615 | $53 | 74% |
|
| Net Cash Flow (TTM) (Mil) | $8 | ($4) | 55% |
|
| Long-Term Debt (Q1) (Mil) | $1,650 | $270 | 72% |
|
| Enterprise Value (Q1) (Mil) | $8,685 | $2,444 | 71% |
|
| Valuation | QGEN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.56 | 2.92 | 60% |
|
| P/E | 21.3 | 43.7 | 54% |
|
| Dividend Yield | 5.8% | 0.0% | 95% |
|
| PEG (5yr hist) | 5.9 | 5.3 | 89% |
|
| Ratios | QGEN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 66.1% | 47.6% | 78% |
|
| Net Margin | 19.2% | (2.9%) | 78% |
|
| ROA | 7.1% | (2.8%) | 80% |
|
| ROE | 11.9% | (4.5%) | 64% |
|
| Liabilities to Assets | 42.4% | 43.0% | 33% |
|
| F-Score | 6 | 5 | 69% |
|
Qiagen N.V. did not pass any screens on 7/31/2026.
